Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.72 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.72 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191643 | 0.84 | SLC22A12 (0.55) | SLC22A12SLC22A6SLC22A8KCNH2L3MBTL1 | |
| Epaminurad SCHEMBL1191165 | 0.84 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1191045 | 0.83 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1190282 | 0.83 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1189980 | 0.83 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1191581 | 0.83 | SLC22A12 (0.98) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1190925 | 0.80 | SLC22A12 (0.91) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| Epaminurad SCHEMBL1190775 | 0.79 | SLC22A12 (0.89) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B2 | |
| SCHEMBL1191645 | 0.78 | SLC22A12 (0.77) | SLC22A12SLC22A6SLC22A8KCNH2CYP11B1 | |
| SCHEMBL1190940 | 0.78 | HSD17B10 (0.51) | SLC22A12SLC22A6SLC22A8L3MBTL1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | claimed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | claimed |
| EP-2266989-B1 | HETEROCYCLIC DERIVATIVES | C & C RES LAB (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394792-B2 | Heterocyclic derivatives | C&C RESEARCH LABORATORIES (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | C&C RESEARCH LABORATORIES (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2266989-A2 | HETEROCYCLIC DERIVATIVES | C&c Research Laboratories (KR) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028467-A1 | HETEROCYCLIC DERIVATIVES | XDH, NUDT1, UGDH | SLC22A12 692/4885SLC22A6 625/4885SLC22A8 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.